Golden Helix · Clinical Genomics Guide

NGS Analysis Software
What to Look For

A buyer-side guide for clinical lab directors and bioinformatics managers. Six pillars for evaluating clinical NGS platforms, how clinical-grade software differs from research tools, and the per-sample-tax trap to avoid.

Six PillarsAnnotation CurrencyACMG AutomationDeterminismISO 13485

Introduction

Software is the operational backbone
of clinical genomics.

The market for NGS analysis software is vast, ranging from open-source command-line tools to comprehensive clinical platforms. For labs moving into production-scale testing, the challenge is not just "finding variants." It is building a reproducible, validated, and automated workflow that holds up under CAP/CLIA inspection.

This guide outlines the six core pillars of professional NGS software evaluation: annotation breadth and currency, clinical interpretation, workflow automation, enterprise scalability, regulatory pedigree, and pricing model. Together they determine your lab's diagnostic yield, turnaround time, and operational scale.

6
Core evaluation pillars for clinical NGS software
ISO 13485
QMS standard for clinical software vendors
Monthly
Minimum annotation database update cadence
8x
WES interpretation speed-up with automated workflow
5+
Variant types a complete platform handles (SNV, indel, CNV, SV, PGx)
21 CFR 11
Electronic records standard audit-ready platforms support

Evaluation Framework

The Six Pillars

Each of these is a real differentiator between clinical-grade platforms and tools that will struggle in a production lab. Use them as the structure for a vendor RFI, an internal evaluation rubric, or a paid-pilot scorecard.

Pillar 1

Annotation Breadth & Currency

Your software is only as good as the data it draws on. Look for monthly curated updates to ClinVar, gnomAD, OMIM, ClinGen, and specialty databases for CNVs, structural variants, and pharmacogenomics. Annotation database versioning must be tracked and auditable for CAP/CLIA compliance.

Pillar 2

Clinical Interpretation Engine

Automated, guideline-driven scoring for ACMG/AMP (germline) and AMP/ASCO/CAP (somatic). The platform should systematically apply criteria to surface a suggested classification while leaving the reviewer in control to adjust criteria and document professional judgment. A classification engine, not a literature-review tool.

Pillar 3

Workflow Automation

From sequencer output to draft report without manual touchpoints. Robust API support, command-line execution, automated QC gating, and parallel processing across compute nodes are essential for scaling lab volume beyond a few cases per week.

Pillar 4

Enterprise Scalability

Multi-user environments with role-based access control. Variant assessment sharing through a knowledgebase so the same variant is never interpreted twice. Flexible deployment options: on-premises, private cloud, or air-gapped, depending on institutional data sovereignty requirements.

Pillar 5

Regulatory Pedigree

Software developed under an ISO 13485-certified Quality Management System. Determinism (same input, same output, every time), comprehensive audit trail, controlled release process, and electronic record controls designed to support CAP, CLIA, and 21 CFR Part 11 requirements.

Pillar 6

Transparent Pricing

Predictable, per-seat or enterprise licensing. Avoid "per-sample" pricing that penalizes the lab for successful growth and creates a tax on every additional case. Pricing should let you forecast software cost independently of throughput.

Tooling Tiers

Open Source vs Sequencer Software vs Clinical Platforms

Three broad tiers of NGS tooling exist. Each has its place. The fit depends on what the lab is trying to accomplish, the regulatory environment, and how much of the operational burden the lab wants to carry directly.

FeatureOpen Source / ScriptsSequencer SoftwareClinical Platform (e.g. VarSeq)
Annotation sourcingManual downloads, manual maintenanceVendor-bundled static catalogsMonthly curated, automated updates
Variant types coveredMostly SNV / indelVendor-specific optimizationsSNV, indel, CNV, SV, PGx, HLA
Clinical scoringExternal websites, manual scoringLimited built-in supportIntegrated ACMG/AMP automation
Data sovereigntyDepends on serverOften cloud-only (SaaS)Full on-prem or private cloud
ReportingCustom scripts, Excel exportsTemplate-based fixed outputClinical-grade PDF, configurable
Quality systemNone (research tools)Varies by vendorISO 13485-certified QMS

The right answer for a research group is often open-source. The right answer for a single-vendor lab tied to one sequencer is often the sequencer-provided software. The right answer for a clinical lab running production diagnostics across multiple assays is a purpose-built clinical platform. The honest framing is matching tier to need, not pretending one tier fits everyone.

ROI

Quantifying the Automation Advantage

The ROI of professional variant analysis software is not just the license cost. It is the hundreds of hours saved by the clinical team every month, and the consistency that comes from systematic evidence gathering rather than manual database queries.

ApproachWES case reviewWhat the workflow looks like
Manual spreadsheet workflow~120 minExternal database queries, manual ACMG application, manual report assembly.
Automated platform (e.g. VarSeq)~15 minPre-aggregated evidence, automated ACMG scoring, pre-populated report templates. Reviewer validates and signs out.

Practical Tool

The Buyer's Evaluation Checklist

Six questions to ask any vendor before signing an evaluation agreement. The answers map directly to the six pillars above and distinguish clinical-grade platforms from research tools.

  • 01

    Curated clinical databases included

    Does the platform provide automated access to ClinVar, gnomAD, OMIM, ClinGen, HGMD, COSMIC, and SpliceAI, with versioning visible in every result? A platform that requires you to manage these yourself is a research tool, not a clinical platform.

  • 02

    CNV and SV without separate tooling

    Can the platform detect and interpret CNVs and structural variants natively, or does it require a second-system handoff? A separate tool for CNVs creates audit-trail fragmentation and validation overhead.

  • 03

    Deterministic and reproducible across versions

    Will the same VCF input produce the same annotated, filtered, classified output every time, on every machine? Any algorithm with random sampling, stochastic behavior, or unlocked version dependencies fails CAP/CLIA reproducibility requirements.

  • 04

    ISO 13485-certified QMS and audit-ready documentation

    Does the vendor operate under a formal quality management system with controlled releases, change management, and complete audit trails? CAP inspectors expect this from clinical software vendors.

  • 05

    Deployment that respects data sovereignty

    Can the platform be kept entirely behind the laboratory firewall, or in a cloud region you control? Institutional policy or GDPR may prohibit multi-tenant SaaS for genomic PHI.

  • 06

    Licensing that does not penalize growth

    Is the model per-seat or fixed enterprise, rather than per-sample? Per-sample pricing makes financial planning impossible and discourages labs from running larger, more comprehensive tests.

Platform Ecosystem

The Golden Helix Stack

Instead of a collection of disconnected NGS analysis tools, Golden Helix provides a unified platform where secondary analysis, tertiary analysis, and data management work as one. Three products, one workflow.

Secondary analysis

Sentieon

High-performance alignment and variant calling, mathematically identical to GATK but optimized for speed and enterprise reliability. The secondary analysis engine that pairs naturally with VarSeq tertiary analysis.

Tertiary analysis

VarSeq + VSClinical

The core platform for tertiary analysis. VSClinical provides guideline-driven ACMG/AMP interpretation and clinical reporting, with automated evidence gathering, phenotype-driven prioritization, and human-in-the-loop reviewer control.

Data management

VSWarehouse

Enterprise variant data management for multi-user labs and multi-site programs. Centralized assessment catalogs, internal allele frequency tracking, reclassification monitoring, and LIMS/EHR integration. Deployed on-premises or in your own cloud.

Common Questions

Software Evaluation FAQ

How do I choose between cloud-based and on-premises NGS software?
Cloud SaaS offers easy setup but often comes with per-sample fees, data sovereignty constraints, and the operational dependency on a vendor's availability and update schedule. On-premises or BYOC (bring-your-own-cloud) deployment, like the Golden Helix platform, allows fixed-cost licensing and keeps patient PHI entirely under your control. For genomic PHI subject to HIPAA or GDPR, deployment flexibility is not a nice-to-have. See the clinical lab infrastructure guide for the full deployment comparison.
Is open-source software suitable for clinical use?
Tools like BWA, GATK, and IGV are powerful and widely used in research. Clinical production environments require additional layers that open-source projects do not provide: controlled versioning tied to clinical validation, comprehensive audit trails, change management under an ISO 13485-certified QMS, and the operational support model that CAP/CLIA accreditation expects. Most clinical labs combine validated open-source secondary analysis tools with a clinical-grade platform for tertiary analysis and reporting, where the regulatory burden is highest.
What is the "per-sample tax" and why does it matter?
Some software vendors charge a fee for every sample processed. This makes financial planning difficult, scales cost linearly with throughput, and discourages labs from running larger or more comprehensive tests. Predictable per-seat or enterprise licensing decouples software cost from sample volume, letting the lab scale without recalculating the budget every quarter. Golden Helix uses a fixed per-seat license model.
How often should NGS annotation databases be updated?
Clinical evidence evolves daily. ClinVar receives thousands of new and updated classifications every month. A platform updating annotations quarterly or less frequently is making clinical decisions on stale evidence: missing newly established Pathogenic classifications, or ignoring reclassifications from Pathogenic to VUS. Monthly curated updates with controlled versioning, traceable on every clinical result, are the minimum standard for CAP/CLIA-compliant interpretation.
What variant types should a clinical platform handle natively?
At minimum: SNVs, small indels, copy number variants (CNVs), structural variants, and pharmacogenomic star alleles. A platform that requires a separate tool for CNVs or SVs creates analytical gaps, audit-trail fragmentation, and additional validation overhead. Native multi-variant-type support is one of the strongest differentiators between research tools and clinical platforms.
How long does clinical NGS interpretation take with vs without automation?
Manual, spreadsheet-based workflows average 2 to 4 hours per WES case. An automated platform with integrated ACMG scoring, phenotype prioritization, and pre-populated report templates reduces hands-on review time to 15 to 30 minutes for routine cases. Complex cases with many VUS candidates still require additional clinical genetics time, but the interpretation bottleneck moves from per-case data wrangling to genuine clinical judgment.

Evaluate the Golden Helix Platform

Ready to see the difference between basic tools and a professional clinical NGS platform? No per-sample fees, on-premises or private-cloud deployment, ACMG/AMP automation built in. Start a free evaluation.